Intellia Therapeutics Inc buy Savour
Start price
24.01.21
/
20%
€63.50
Target price
24.01.22
-
Performance (%)
-15.72%
End price
11.03.21
€53.52
Summary
This prediction ended on 11.03.21 with a price of €53.52. The price of Intellia Therapeutics Inc has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -15.72%. Savour has 20% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Intellia Therapeutics Inc | 8.566% | 8.566% | 11.686% | -68.605% |
| iShares Core DAX® | -0,38 % | 1,09 % | 11,64 % | 60,42 % |
| iShares Nasdaq 100 | -0,41 % | -1,97 % | 7,27 % | 87,82 % |
| iShares Nikkei 225® | 1,84 % | 10,26 % | 31,38 % | 66,93 % |
| iShares S&P 500 | -0,71 % | 0,44 % | 4,30 % | 60,46 % |
According to Savour what are the pros and cons of Intellia Therapeutics Inc for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by Savour for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Buy Intellia Therapeutics Inc